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472 wileyonlinelibrary.com/journal/gpsObjectives: Antipsychotics are used to manage the behavioral and psychological
symptoms of dementia (BPSD), despite their association with greater risks for mortal-
ity and cerebrovascular events. Previous studies in Japan have estimated the preva-
lence of antipsychotics among older adults who took antidementia drugs. Using
long‐term care (LTC) data, we aimed to obtain more accurate estimates of the
prevalence of antipsychotics and to determine factors related to their use in older
adults with dementia.
Methods: Medical and LTC claims data and LTC certification data between April
2012 and September 2013 were obtained from a middle‐sized suburban city. The
1‐year prevalence of antipsychotic use was estimated among individuals with proba-
ble dementia aged greater than or equal to 75 years who were prescribed
antidementia drugs and/or had dementia based on LTC needs certification data.
Results: Of 25 919 participants, 4865 had probable dementia and 1506 were
prescribed antidementia drugs. The prevalence of antipsychotics among participants
with probable dementia was 10.7%, which was lower than that in those who were
prescribed antidementia drugs (16.4%). Among participants with probable dementia
with LTC certification data available (N = 4419), lower cognitive function (vs mild;
adjusted odds ratio 2.16, 95% confidence interval 1.63‐2.86), antidementia drug use
(2.27, 1.84‐2.81), and institutional LTC services use (2.34, 1.85‐2.97) were associated
with greater odds of antipsychotic use, whereas older age (greater than or equal to
92 years) was associated with lower odds (vs less than 77 years; 0.42, 0.27‐0.65).
Conclusions: These findings may be useful for estimating the burden of BPSD and
for taking measures to reduce inappropriate antipsychotic prescription.
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Key points
• Previous studies in Japan determined the prevalence
of antipsychotics among individuals prescribed
antidementia drugs because of the unavailability of
reliable data.
• Use of long‐term care data enabled us to obtain more
accurate estimates of the prevalence of antipsychotic
use in older adults with dementia.
• The new population‐based estimate of the prevalence of
antipsychotics (10.7%) was lower than that estimated
among people prescribed antidementia drugs (16.4%).
• Younger age, institutional LTC services use, antidementia
drug use, and lower cognitive function were associated
with greater odds of antipsychotic use.
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Japan has the greatest number of people with dementia among the Organi-
sation for EconomicCo‐operation andDevelopment countries.1 This number
is projected to increasemarkedly in the near future, reaching almost one‐fifth
of the population2 over 65 years in 2025. This could impose considerable
financial and social burdens on both the health care system and society.
One of the major challenges of caring for people with dementia is
managing the behavioral and psychological symptoms of dementia
(BPSD).3 Antipsychotics have been used for BPSD management,
despite off‐label use.4 Indeed, antipsychotics are associated with
greater risks for mortality and cerebrovascular events, which has led
regulatory agencies to issue warnings or required pharmaceutical com-
panies to add precautions about the use of antipsychotics for people
with dementia.4-7 However, antipsychotics have still been commonly
prescribed in older adults with dementia in Japan8-10 and in overseas
countries,11,12 even after the issue of such warnings or precautions.
There have been several studies on the use of antipsychotics in older
people with dementia in Japan. Based on analyses of large‐scale medical
claims data, the prevalence of antipsychotic use among people prescribed
antidementia drugs8-10 ranged from 16.8% to 24.9%. These studies limited
their study cohort to those prescribed antidementia drugs partly because a
diagnosis of dementia in medical claims is not considered reliable. How-
ever, the generalizability of such estimates is limited because people with
dementia do not always take antidementia drugs. In fact, the indication
for antidementia drugs is generally limited to Alzheimer dementia, with
the exception of donepezil, which has been also approved for dementia
with Lewy bodies in Japan. Moreover, antidementia drugs are not always
prescribed for older adults with dementia for efficacy and safety reasons.13
Since 2000, Japan has implemented a long‐term care (LTC) insur-
ance system that is separate from the medical insurance system.14 To
become beneficiaries of LTC insurance, individuals must have their
LTC needs certified through a standardized process involving an
assessment of physical and cognitive functions.15 Lowered cognitive
function determined through this process is potentially more clinically
relevant than those diagnoses listed in medical claims data16; accord-
ingly, LTC needs certification data might be better able to identify
older people with dementia and cognitive decline.
The main objective of this study was to provide a potentially more
accurate estimate of the prevalence of antipsychotic use among older
adults with dementia, irrespective of whether they have been pre-
scribed antidementia drugs, using medical and LTC data in Japan. As
the medical and LTC data can be linked, we are able to identify people
with dementia, regardless of whether they are being treated with
antidementia drugs. The secondary objective was to determine the
factors associated with antipsychotic use in older people with demen-
tia using the LTC certification data.FIGURE 1 Flow diagram for participant selection. Probable
dementia is defined as antidementia drug users and those with rank I
or greater on the “Independence Degree of Daily Living for the
Dementia.” LTC, long‐term care2 | MATERIALS AND METHODS
2.1 | Data sources
Medical and LTC claims data and LTC certification data over
18 months (April 2012 to September 2013) were obtained from amiddle‐sized suburban city in the Tokyo metropolitan area of Japan.
Before they were obtained, all data were anonymized; however,
unique identification numbers were assigned to each person to enable
matching between the medical and LTC data. During the
anonymization process, birth year was approximated by converting it
to a 5‐year range (eg, people born between 1930 and 1934 would
be 77‐81 years of age as of January 1, 2012). This study was approved
by the Ethics Committee of the University of Tsukuba.2.2 | Study participants
Figure 1 presents a flow chart of participant selection. People eligible
for the Late Elders' Health Insurance system at entry were included
(N = 37 998). This system provides medical insurance to all residents
over 75 years as well as those aged 65 to 74 years with disabilities.
474 KURODA ET AL.We attempted to simplify the dataset to those over 75; however, we
were not able to exclude people aged 72 to 74 years who were eligible
for the Late Elders' Health Insurance system because the birth year
data were available only in 5‐year ranges. Based on the national statis-
tics, people aged 72 to 74 years with the Late Elders' Health Insurance
were estimated to account for less than 1% of the category of those
aged 72 to 76 years in this study. Because the data did not include
participants' insurance eligibility information, including information
about their deaths, we selected participants with 12 or more months
of data, based on the first and last claims records. To obtain the 1‐year
prevalence of antipsychotic use for comparability with previous stud-
ies,8-10 we used the first 12 months of data for our analyses. We also
excluded participants who stayed in hospitals or specific types of LTC
facilities using bundled payment schemes for more than 6 months in
total as their prescription data during their stay there would be
unavailable. We could not obtain claims data on medical services for
individuals covered by public assistance, so these individuals were
not included in the study.
We analyzed the following three cohorts based on our study aims
(Figure 2).
1. Probable dementia (novel cohort identification): This group
included both antidementia drug users and those with rank I or
greater on the “Independence Degree of Daily Living for the
Demented,” a measure used in the process of LTC needs
certification.16,17
2. Antidementia drug users (conventional cohort identification):
These were participants who were prescribed antidementia
drugs. We evaluated this cohort to enable a comparison with pre-
vious studies.8-10
3. Probable dementia with LTC needs certification data: This group
was a subset of the probable dementia cohort defined above
for evaluation of associations of factors, including physical and
cognitive function, with antipsychotic use. Therefore, in this
group, participants that were identified as having probable
dementia based on antidementia drug prescription but had not
been certified for their LTC needs were excluded.FIGURE 2 Illustration of the study cohorts. LTC, long‐term care2.3 | Antipsychotic and antidementia drugs
We included both typical and atypical antipsychotic drugs being
marketed in Japan during the study period. The typical antipsychotics
included bromperidol, carpipramine, chlorpromazine, clocapramine, flu-
phenazine, haloperidol, levomepromazine, mosapramine, nemonapride,
oxypertine, perphenazine, pimozide, pipamperone, prochlorperazine,
propericiazine, spiperone, sulpiride, sultopride, timiperone, trifluopera-
zine, and zotepine. The atypical antipsychotics included aripiprazole,
blonanserin, clozapine, olanzapine, paliperidone, perospirone, quetiapine,
and risperidone. As a sensitivity analysis, we repeated the analyses
while excluding prochlorperazine and sulpiride, as the former is generally
used as an antiemetic and the latter for gastric discomfort in Japan.
We included all four antidementia drugs to identify antidementia
drug users: donepezil, rivastigmine, galantamine, and memantine. Par-
ticipants who had at least one outpatient prescription of any of these
antidementia drugs during the 12‐month study period were defined as
antidementia drug users.2.4 | Physical and cognitive function
Activities of daily living associated with dementia and physical disability
were only available for participants who had LTC needs certification
data. The primary goal of LTC needs certification is to determine both
eligibility and individuals' care needs level (which falls into seven
grades) based on assessment of physical and cognitive functions; it is
usually reassessed once every 12 or 24 months. The assessment proce-
dures are standardized nationwide and involve interviews with the
older adult in question and their primary caregiver, as well as a primary
care physician's opinion. In this study, the most recent physical and
cognitive functions data prior to the study entry were considered.
For cognitive disability, we used the “Independence Degree of
Daily Living for the Demented.”17 This measure was validated for
identifying people aged greater than or equal to 65 years with demen-
tia in the community with reference to a diagnosis of dementia made
by neuropsychiatrists as the gold standard.16 When people without
LTC certification were categorized into those without dementia, the
cut‐off of rank I on this measure had a 65% sensitivity and a 93%
specificity. For people who received LTC services, the validity of this
method was improved (83% sensitivity and 92% specificity).16 It was
also reported that most people aged greater than or equal to 65 years
with dementia (~80%) had applied for LTC needs certification.16 We
deemed individuals with rank I (almost independent daily living is pos-
sible despite having some type of dementia) or greater as having prob-
able dementia. More specifically, individuals were grouped into mild
(rank I), moderate (rank II; independent daily life is possible under
observation despite daily life‐disturbing symptoms, behaviors, and
problems with communication), or severe (rank III, requiring assis-
tance; rank IV, requiring assistance frequently; or rank M, marked psy-
chiatric symptoms requiring expert management) cognitive disability.
Physical disability was determined according to the scale of
“Independence Degree of Daily Living for the Disabled Elderly”
(Independent, J1/J2, A1/A2, B1/B2, and C1/C2).17 In this study, these
ratings were categorized into “not bedridden” (Independent, J1/J2,
and A1/A2) and “bedridden” (B1/B2 and C1/C2).
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The demographics of the study participants were described. The main
outcomemeasurewas the prevalence of at least one outpatient prescrip-
tion of an antipsychotic over the 12‐month study period. The prevalence
of antipsychotic use was estimated for each study cohort defined above.
We also evaluated the associations of age, gender, antidementia
drug use, residential status, hospitalization, and cognitive and physical
disability with antipsychotic use among participants with probable
dementia whose LTC needs certification data were available. A logistic
regression analysis, assessing crude and adjusted odds ratios and 95%
confidence intervals, was used for this purpose. Residential status was
derived from the LTC claims data. Participants who had at least one
claim for institutional LTC services use, including use of one of the
three designated types of LTC facilities18 and other types of facilities
or group homes for older people during the 12‐month study period,
were categorized as LTC facility users. Hospitalization was derived
from the medical claims data; participants who had at least one claim
for inpatient treatment during the study period were categorized as
people who had experienced hospitalization.
As a sensitivity analysis, we repeated the analysis of the 6‐month
prevalence of antipsychotics in those who had at least 6 months of
follow‐up. All analyses were performed using Stata version 14 (Stata
Corp., College Station, Texas).
3 | RESULTS
This study included 25 919 participants, among which a quarter were
LTC beneficiaries (n = 6106). Participants with probable dementia andTABLE 1 Characteristics of the study participants
Participants With
Probable Dementia
Antidementia Dru
Users
n = 4865 n = 1506
n % n %
Age, years
72‐76a 580 11.9 196 13
77‐81 1198 24.6 475 31
82‐86 1394 28.7 488 32
87‐91 1117 23.0 278 18
≥92 576 11.8 69 4
Sex
Male 1400 28.8 459 30
Female 3465 71.2 1,047 69
Antidementia drugs
No 3359 69.0 NA NA
Yes 1506 31.0 1506 100
Hospitalization
No 3961 81.4 1,285 85
Yes 904 18.6 221 14
LTC needs certification
No 446 9.2 446 29
Yes 4419 90.8 1060 70
Abbreviation: LTC, long‐term care.
aPeople <75 were included only if eligible for the Late Elders' Health Insuranceantidementia drug users accounted for 18.8% (n = 4865) and 5.8%
(n = 1506), respectively, of the overall sample. When participants with
probable dementia were first identified by the use of antidementia
drugs (n = 1506; 31.0%), LTC data contributed to identifying an addi-
tional 3359 participants (69.0%). Conversely, when LTC data were first
used to identify participants with probable dementia (n = 4337;
89.1%), the use of antidementia drugs contributed to identifying an
additional 528 participants (10.9%).
The characteristics of people with probable dementia and
antidementia drug users, and their proportions of the study population,
are shown inTable 1. The proportion of people with probable dementia
increased with age, ranging from 7% to 70%; the proportion of
antidementia drug users ranged from 3% to 12% according to age. The
difference in proportion between these two cohorts increasedwith age.
Table 2 shows the prevalence of antipsychotic use according to
age group, sex, and LTC certification status. The prevalence of anti-
psychotic use was 10.7% among participants with probable dementia,
16.4% among antidementia drug users, 2.1% among participants with-
out probable dementia, and 3.8% for the entire study population. In
the sensitivity analysis that excluded prochlorperazine and sulpiride,
the corresponding prevalence proportions were 9.1%, 14.8%, 0.7%,
and 2.3%, respectively (Table S1). Among antidementia drug users,
atypical antipsychotics were more commonly used, whereas typical
antipsychotics were slightly more commonly used among participants
with probable dementia (Table 2). When prochlorperazine and
sulpiride were excluded, atypical antipsychotics were more commonly
used among all three cohorts (Table S1). The 6‐month prevalence of
antipsychotic use (N = 31 353) was 9.1% among participants withg
All Participants
Participants Identified As:N = 25 919
n %
Having Probable
Dementia, %
Antidementia
Drug Users, %
.0 7812 30.1 7.4 2.5
.5 9647 37.2 12.4 4.9
.4 5294 20.4 26.3 9.2
.5 2328 9.0 48.0 11.9
.6 838 3.2 68.7 8.2
.5 10 684 41.2 13.1 4.3
.5 15 235 58.8 22.7 6.9
24 413 94.2 13.8 NA
.0 1506 5.8 100.0 100.0
.3 22 746 87.8 17.4 5.6
.7 3173 12.2 28.5 7.0
.6 19 813 76.4 2.3 2.3
.4 6106 23.6 72.4 17.4
system.
TABLE 2 One‐year prevalent users of antipsychotics according to dementia status and the characteristics of the study participants
Participants With
Probable Dementia
Antidementia Drug
Users
Participants With Probable
Dementia With LTC
Certification Data Available
Participants Without
Probable Dementia All Participants
n = 4865 n = 1506 n = 4419 n = 21 054 N = 25 919
n % n % n % n % n %
All 520/4865 10.7 247/1506 16.4 478/4419 10.8 452/21 054 2.1 972/25,919 3.8
Age, years
72‐76a 71/580 12.2 33/196 16.8 59/486 12.1 148/7232 2.0 219/7812 2.8
77‐81 149/1198 12.4 72/475 15.2 138/1015 13.6 196/8449 2.3 345/9647 3.6
82‐86 154/1394 11.1 87/488 17.8 141/1272 11.1 76/3900 1.9 230/5294 4.3
87‐91 106/1117 9.5 47/278 16.9 102/1076 9.5 30/1211 2.5 136/2328 5.8
≥92 40/576 6.9 8/69 11.6 38/570 6.7 2/262 0.8 42/838 5.0
Sex
Male 133/1400 9.5 68/459 14.8 119/1209 9.8 139/9284 1.5 272/10 684 2.6
Female 387/3465 11.2 179/1047 17.1 359/3210 11.2 313/11 770 2.7 700/15 235 4.6
LTC needs certification
No 42/446 9.4 42/446 9.4 NA NA 403/19 367 2.1 445/19 813 2.3
Yes 478/4,419 10.8 205/1,060 19.3 NA NA 49/1687 2.9 527/6106 8.6
By type of antipsychotics
Atypical 227/4865 4.7 120/1506 8.0 207/4419 4.7 72/21 054 0.3 299/25 919 1.2
Typical 243/4865 5.0 101/1506 6.7 225/4419 5.1 354/21 054 1.7 597/25 919 2.3
Bothb 50/4865 1.0 26/1506 1.7 46/4419 1.1 26/21 054 0.1 76/25 919 0.3
Abbreviation: LTC, long‐term care.
aPeople <75 were included only if eligible for the Late Elders' Health Insurance system.
bConcurrent or sequential use during the study period.
476 KURODA ET AL.probable dementia, 14.9% among antidementia drug users, 1.8%
among participants without probable dementia, and 3.1% for the
entire study population.
Among participants with probable dementia with LTC certification
data available (n = 4419; 90.8% of those with probable dementia),
there were slightly more people with moderate and severe cognitive
disabilities than there were those with mild cognitive disability
(Table 3). Furthermore, 1.5% (n = 66) were in rank M (marked psychi-
atric status) at the time of LTC needs assessment.
A multivariate logistic regression analysis revealed that severe (vs
mild; adjusted odds ratio 2.16, 95% confidence interval 1.63‐2.86,
P < 0.001) and moderate cognitive disability (1.34, 1.01‐1.77,
P = 0.045), antidementia drug use (vs nonuse; 2.27, 1.84‐2.81,
P < 0.001), and institutional LTC services use (vs nonuse; 2.34,
1.85‐2.97, P < 0.001) were associated with greater odds of antipsy-
chotic use. By contrast, older age, including 87 to 91 years (0.62,
0.43‐0.88, P < 0.01) or greater than or equal to 92 years (0.42,
0.27‐0.65, P < 0.001), was associated with lower odds of using
antipsychotics when compared with the lowest age group (less than
77 years) (Table 3).4 | DISCUSSION
By applying a comprehensive approach to dementia identification, we
demonstrated that the prevalence of antipsychotic use among people
with probable dementia in Japan was 10.7%. This is the first estimate
of the prevalence of antipsychotic use among a large population ofpeople with dementia that is not limited to antidementia drug users
in Japan. The estimated prevalence of antipsychotic use is comparable
with that in France (10.2%) but higher compared with that found in
the United Kingdom (7.4%) and lower than that in the United States
(14.9%), respectively.19-21
This new prevalence estimate is lower than that derived from
antidementia drug users only. A previous study using a nationally rep-
resentative medical claims database in Japan revealed that the preva-
lence of antipsychotics among people taking donepezil was about 25%
(N = 15 591) and demonstrated a slightly increasing trend8 between
2002 and 2010. More recently, the prevalence of antipsychotic use
among antidementia drug users after three further antidementia drugs
began being marketed in Japan was determined to be 18.9%
(N = 75 011) and 16.8% (N = 45 437); these latter two estimates were
similar to our own among antidementia drug users (16.4%).9,10 We
also confirm a previously reported shift from typical to atypical anti-
psychotic use in older people with dementia in Japan.8
Possible reasons for the decreased prevalence of antipsychotic
use among antidementia drug users in more recent studies are the
accumulated evidence of the adverse effects of antipsychotic use in
people with dementia4 and the corresponding safety warnings issued
by the Japanese regulatory authority7 in 2009. Another possible rea-
son is the increased use of memantine since its introduction9 in
2011. Although controversy remains about whether memantine has
a beneficial effect on BPSD,22 previous observational studies imply
that initiation of memantine reduces the consumption of psychotro-
pics23 and antipsychotics.24 More recently, the “Primary Care Physi-
cians' Guideline of Psychotropic Use for BPSD” was published in
TABLE 3 Associations of participant characteristics with antipsychotic use among participants with probable dementia with LTC certification
data available (n = 4419)
Crude Adjusted
N % Odds Ratio 95% CI P Odds Ratio 95% CI P
Age, years
72‐76a 486 11.0 Reference Reference
77‐81 1015 23.0 1.14 0.82‐1.58 0.435 1.03 0.73‐1.44 0.872
82‐86 1,272 28.8 0.90 0.65‐1.25 0.533 0.74 0.53‐1.04 0.080
87‐91 1,076 24.3 0.76 0.54‐1.06 0.110 0.62 0.43‐0.88 0.008
≥92 570 12.9 0.52 0.34‐0.79 0.002 0.42 0.27‐0.65 <0.001
Sex
Male 1,209 27.4 Reference Reference
Female 3,210 72.6 1.15 0.93‐1.44 0.201 1.18 0.94‐1.49 0.154
Institutional LTC services use
No 3,749 84.8 Reference Reference
Yes 670 15.2 2.57 2.07‐3.20 <0.001 2.34 1.85‐2.97 <0.001
Antidementia drug use
No 3,359 76.0 Reference Reference
Yes 1,060 24.0 2.71 2.23‐3.30 <0.001 2.27 1.84‐2.81 <0.001
Hospitalization
No 3,569 80.8 Reference Reference
Yes 850 19.2 1.00 0.79‐1.27 0.994 1.03 0.80‐1.33 0.803
Cognitive disability
Mild 1,288 29.2 Reference Reference
Moderate 1,628 36.8 1.50 1.14‐1.97 0.004 1.34 1.01‐1.77 0.045
Severe 1,503 34.0 2.72 2.10‐3.53 <0.001 2.16 1.63‐2.86 <0.001
Physical disability
Not bedridden 3,114 70.5 Reference Reference
Bedridden 1,305 29.5 1.03 0.84‐1.27 0.763 0.93 0.74‐1.17 0.541
Abbreviation: LTC, long‐term care.
aPeople <75 were included only if eligible for the Late Elders' Health Insurance system.
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and further studies are needed to evaluate the use of antipsychotics
for BPSD with more recent data.
We found that antipsychotic use was associated with younger
age, greater cognitive disability, use of antidementia drugs, and use
of institutional LTC services. The observed dose‐response relationship
between cognitive disability and antipsychotic use suggests that anti-
psychotic prescription is partly explained by BPSD itself. Excessive use
of antipsychotics in nursing homes has been an important issue inter-
nationally.25-27 The observed association of institutional LTC services
use with greater antipsychotic use in the present study may suggest
that nursing home residence might be conductive to antipsychotic
use in Japan. The development of nonpharmacological BPSD manage-
ment and antipsychotic withdrawal techniques feasible for use are
strongly desired. In addition, future studies might examine the possible
influence of antidementia drug prescriptions on the subsequent
course of BPSD and antipsychotic prescriptions.
The strength of this new approach is that it offers greater sensitiv-
ity for identifying people with dementia in the population compared
with the conventional method using medical claims data only.
Antidementia drug users accounted for only 30% of people with proba-
ble dementia, suggesting that the majority of people with dementiacould not have been identified in previous studies.8-10 The age‐
stratified prevalence of probable dementia in our study was similar to
that identified using the Diagnostic and Statistical Manual of Mental
Disorders, Third Edition‐revised (DSM‐III‐R)28 in the latest epidemiolog-
ical study in Japan.29 Moreover, the prevalence of antipsychotic use
other than prochlorperazine and sulpiride in participants without prob-
able dementia was similar to the prevalence of schizophrenia among
individuals aged over 70 years in Japan (male 0.4%, female 0.6%).30
This suggests that the new method almost completely succeeded in
identifying participants with dementia receiving antipsychotics.
However, there are several limitations in this study. First, we
could not determine whether the antipsychotics were prescribed to
relieve BPSD or not because of their off‐label use. Some antipsy-
chotics could have been used for the treatment of bipolar disorder
or, despite their off‐label use, for delirium or depression. Second, we
did not evaluate the validity of the classification of dementia using
the gold standard in our study population. While our approach could
have effectively identified the majority of people with dementia, some
people with dementia who did not receive antidementia drugs during
the study period or did not apply for LTC needs certification could not
be identified. Because people with dementia but who do not take
antidementia drugs or have LTC needs certification are the least likely
478 KURODA ET AL.to receive antipsychotics, our numbers on the prevalence of antipsy-
chotic use might be slightly overestimated. Third, we did not include
individuals censored within 12 months after their entry (eg, died) or
who had neither medical nor LTC services use during the study period.
Fourth, we should be careful about generalizing our results, as they are
based on the residents of a single city. For example, based on the
association of institutional LTC services use with antipsychotic use,
the prevalence of antipsychotic use may vary by region according to
the availability of institutional LTC facilities. However, the prescribing
of antipsychotics for BPSD in our study population is not considered
to be very different from that in the entire Japanese population
because the prevalence of antipsychotic use among antidementia drug
users was similar to that reported in previous studies with nationwide
samples.9,10 Fifth, causal relationships between the identified factors
and antipsychotic use cannot be established because of our cross‐
sectional design and 1‐year time window. Finally, we did not know
the precise health status of each individual when they were issued
the antipsychotic prescription because there were time differences
between this prescription and their assessment of cognitive and phys-
ical function for the LTC needs certification.
In conclusion, we have provided a comprehensive population‐
based estimate of the prevalence of antipsychotic use and its related
factors among older people with dementia in Japan. This potentially
more accurate estimation of the prevalence of antipsychotic use may
be useful for policymakers in estimating the burden of BPSD and in
taking measures to reduce inappropriate antipsychotic prescription in
older adults with dementia.
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